Amylyx Pharmaceuticals Inc (AMLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 71,428 | 21,885 | 345 | 0 | 0 |
| Cost of Goods | 5,283 | 2,821 | 172 | N/A | N/A |
| Gross Profit | 66,145 | 19,064 | 173 | N/A | N/A |
| Operating Expenses | 68,481 | 64,478 | 55,026 | 54,253 | 47,814 |
| Operating Income | -2,053 | -44,593 | -54,681 | -54,253 | -47,814 |
| Other Income | 3,456 | 2,468 | 800 | 360 | 112 |
| Pre-tax Income | 1,403 | -42,125 | -53,881 | -53,893 | -47,702 |
| Income Tax | -170 | 579 | -125 | 174 | 146 |
| Net Income Continuous | 1,573 | -42,704 | -53,756 | -54,067 | -47,848 |
| Net Income | $1,573 | $-42,704 | $-53,756 | $-54,067 | $-47,848 |
| EPS Basic Total Ops | 0.02 | -0.61 | -0.92 | -0.93 | -0.93 |
| EPS Basic Continuous Ops | 0.02 | -0.62 | -0.92 | -0.93 | -0.93 |
| EPS Diluted Total Ops | 0.02 | -0.61 | -0.92 | -0.93 | -0.93 |
| EPS Diluted Continuous Ops | 0.02 | -0.62 | -0.92 | -0.93 | -0.93 |
| EPS Diluted Before Non-Recurring Items | 0.02 | -0.65 | -0.92 | N/A | N/A |
| EBITDA(a) | $-4,752 | $-46,271 | $-54,605 | $-54,257 | $-47,777 |